The Neuronal Acetylcholine Receptor Subunit Alpha 7 pipeline drugs market research report outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Neuronal Acetylcholine Receptor Subunit Alpha 7 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Cardiovascular, Gastrointestinal, and Oncology which include the indications Alzheimer’s Disease, Schizophrenia, Acute Ischemic Stroke, Dysphagia, and Unspecified Cancer. It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 targeted therapeutics development with respective active and dormant or discontinued products.
The Neuronal Acetylcholine Receptor Subunit Alpha 7 pipeline targets constitutes close to 15 molecules. Out of which, approximately 13 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 2, 1, 3, and 7 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Neuronal Acetylcholine Receptor Subunit Alpha 7 overview
Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
For a complete picture of Neuronal Acetylcholine Receptor Subunit Alpha 7’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
